The Stanozolol hormone can be one of the few anabolic androgenic steroids women can use safely; while it is not the absolute mildest in nature for a woman it is up high on the list. Issues regarding the steroids hepatic nature as well as its effects on lipid profiles remain the same with women but the female athlete must also necessarily be aware of virilization. For the female athlete, the Winstrol side effects revolving around virilization will be the most concerning as such effects can destroy a womans femininity. Common virilization effects include a deepening of the vocal chords, body-hair growth and enlargement of the clitoris. The majority of women who supplement with the Stanozolol hormone, if they keep the dose low and use for very short periods will be fine. If you are a female Winstrol user and you begin to notice virilization symptoms simply discontinue use and you will be fine; nothing will change. It is when the symptoms are ignored, use is continued and the symptoms are allowed to set in that many women develop a problem; remember, man or woman responsible use is always your best friend.
Rabbia and Pini (2010) stated that atherosclerotic renovascular disease is an increasingly recognized cause of severe hypertension and declining kidney function. Patients with atherosclerotic renovascular disease have been demonstrated to have an increased risk of adverse cardiovascular events. In the past 20 years, renal artery re-vascularization for treatment of ARAS has gained great increase via percutaneous techniques. However the effectiveness of contemporary re-vascularization therapies in the treatment of RAS is unproven and controversial. The indication for renal artery stenting is widely questioned due to a not yet proven benefit of renal re-vascularization compared to best medical therapy. Many authors question the effectiveness of percutaneous renal re-vascularization on clinical outcome parameters, such as preservation of renal function and BP control. None of the so far published RCTs could prove a beneficial outcome of RAS re-vascularization compared with medical management.